tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2024-029tumors-1427Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISЭкспрессия CD155 (рецептора полиовируса человека) как неблагоприятный прогностический фактор течения меланомы хориоидеиExpression of the human poliovirus receptor (CD155) as an unfavorable prognostic factor for the choroid melanomahttps://orcid.org/0000-0002-5134-3666ЖеркоИ. Ю.ZherkaI. Yu.

Жерко Ирина Юрьевна

223040 Минск, аг. Лесной

Zherka Iryna Yurevna

Lesnoy, Minsk 223040

zherko.irina@mail.ruhttps://orcid.org/0000-0002-2251-6089ДавыдовД. А.DavydovD. A.

Давыдов Денис Александрович

223040 Минск, аг. Лесной

Davydov Denis Aleksandrovich

Lesnoy, Minsk 223040

https://orcid.org/0009-0001-8615-649XШупиловаЕ. П.ShupilovaE. P.

Шупилова Екатерина Павловна

223040 Минск, аг. Лесной

Shupilova Ekaterina Pavlovna

Lesnoy, Minsk 223040

https://orcid.org/0009-0003-2015-0364МогилянчикА. Ф.MahilyanchykA. F.

Могилянчик Александра Федоровна

223040 Минск, аг. Лесной

Mogilyanchik Aleksandra Fedorovna

Lesnoy, Minsk 223040

https://orcid.org/0000-0003-2399-117XПортянкоА. С.PortyankoA. S.

Портянко Анна Сергеевна

223040 Минск, аг. Лесной

Portyanko Anna Sergeevna

Lesnoy, Minsk 223040

ГУ «Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова»БеларусьN. N. Alexandrov National Cancer Centre of BelarusBelarus2024230120251447076Copyright © Жерко И.Ю., Давыдов Д.А., Шупилова Е.П., Могилянчик А.Ф., Портянко А.С., 20252025Жерко И.Ю., Давыдов Д.А., Шупилова Е.П., Могилянчик А.Ф., Портянко А.С.Zherka I.Y., Davydov D.A., Shupilova E.P., Mahilyanchyk A.F., Portyanko A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1427Цель

Цель: охарактеризовать экспрессию CD155 в клетках первичной меланомы хориоидеи и определить ее прогностическое значение в отношении показателей выживаемости.

Материал и методы

Материал и методы: включено 68 пациентов с первичной меланомой хориоидеи. Иммуногистохимическим методом изучены уровни и паттерны экспрессии CD155 в тканях опухоли. Проведен регрессионный анализ для выявления независимых факторов прогноза течения заболевания.

Результаты

Результаты: в 51% случаев зарегистрирована мембранная экспрессия CD155 клетками меланомы хориоидеи. В группе опухолей с наличием любого типа мембранной экспрессии CD155 статистически значимо чаще встречались признаки неблагоприятного прогноза. Установлено, что мембранная экспрессия CD155 является независимым прогностическим фактором в отношении развития отдаленных метастазов по данным многофакторного регрессионного анализа (ОР 3,795% ДИ 1,3–10,4, р = 0,005), а также в отношении смерти от меланомы хориоидеи (ОР 3,295% ДИ 1,2–8,3, р = 0,009).

Заключение

Заключение: были изучены особенности и паттерны экспрессии СD155 в первичной меланоме хориоидеи. Установлено, что наличие мембранной экспрессии СD155 ассоциировано с увеличением риска прогрессирования заболевания в 3,7 раза, смерти — в 3,2 раза. Для клинического использования выявленных закономерностей требуется валидация модели в проспективном исследовании.

Aim

Aim: to characterize CD155 expression in primary choroidal melanoma cells and determine its prognostic value for survival.

Material and methods

Material and methods: 68 patients with primary choroidal melanoma were included. The levels and patterns of CD155 expression in tumor tissues were studied using immunohistochemical method. Regression analysis was performed to identify independent factors predicting the course of the disease.

Results

Results: in 51 % of cases, membrane expression of CD155 was registered in choroidal melanoma cells. In the group of tumors with any type of membrane expression of CD155, the signs of poor prognosis were statistically significantly more common. Membrane expression of CD155 was found to be an independent prognostic factor for the development of distant metastases according to multivariate regression analysis (RR 3.7 95 % CI 1.3–10.4, p = 0.005), as well as for death from choroidal melanoma (RR 3.2 95 %CI 1.2–8.3, p = 0.009).

Conclusion

Conclusion: the expression patterns of CD155 in primary choroidal melanoma were studied. It was found that the presence of membrane expression of CD155 was associated with an increased risk of choroid melanoma progression by 3.7 times and death by 3.2 times.

меланома хориоидеииммунный инфильтратпрогнозСD155choroidal melanomaimmune infiltrateprognosisCD155Статья подготовлена без спонсорской поддержки.The article was prepared without sponsorship.ReferencesJager M.J., Shields C.L., Cebulla C.M., et al. Uveal melanoma. Nat Rev Dis Primers 2020;6(1):24. https://doi.org/10.1038/s41572-020-0158-0Jager M.J., Shields C.L., Cebulla C.M., et al. Uveal melanoma. Nat Rev Dis Primers 2020;6(1):24. https://doi.org/10.1038/s41572-020-0158-0Algazi A.P., Tsai K.K., Shoushtari A.N., et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016;122(21):3344–3353. https://doi.org/10.1002/cncr.30258Algazi A.P., Tsai K.K., Shoushtari A.N., et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016;122(21):3344–3353. https://doi.org/10.1002/cncr.30258Dhillon S. Tebentafusp: First Approval. Drugs 2022;82(6):703–710. https://doi.org/10.1007/s40265-022-01704-4Dhillon S. Tebentafusp: First Approval. Drugs 2022;82(6):703–710. https://doi.org/10.1007/s40265-022-01704-4Petrausch U., Martus P., Tönnies H., et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008;22(8):997–1007. https://doi.org/10.1038/sj.eye.6702779Petrausch U., Martus P., Tönnies H., et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008;22(8):997–1007. https://doi.org/10.1038/sj.eye.6702779Onken M.D., Worley L.A., Tuscan M.D., Harbour J.W. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12(4):461–468. https://doi.org/10.2353/jmoldx.2010.090220Onken M.D., Worley L.A., Tuscan M.D., Harbour J.W. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12(4):461–468. https://doi.org/10.2353/jmoldx.2010.090220Aaberg T.M. Jr, Cook R.W., Oelschlager K., et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol 2014;8:2449–60. https://doi.org/10.2147/OPTH.S70839Aaberg T.M. Jr, Cook R.W., Oelschlager K., et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol 2014;8:2449–60. https://doi.org/10.2147/OPTH.S70839Carvajal R.D., Sacco J.J., Jager M.J., et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol 2023;20(2):99–115. https://doi.org/10.1038/s41571-022-00714-1Carvajal R.D., Sacco J.J., Jager M.J., et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol 2023;20(2):99–115. https://doi.org/10.1038/s41571-022-00714-1Onken M.D., Worley L.A., Char D.H., et al. Collaborative ocular Oncology Group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119(8):1596–1603. https://doi.org/10.1016/j.ophtha.2012.02.017Onken M.D., Worley L.A., Char D.H., et al. Collaborative ocular Oncology Group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119(8):1596–1603. https://doi.org/10.1016/j.ophtha.2012.02.017Mezheyeuski A., Backman M., Mattsson J., et al. An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. EBioMedicine 2023;88:104452. https://doi.org/10.1016/j.ebiom.2023.104452Mezheyeuski A., Backman M., Mattsson J., et al. An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. EBioMedicine 2023;88:104452. https://doi.org/10.1016/j.ebiom.2023.104452Bakhoum M.F., Esmaeli B. Molecular characteristics of uveal melanoma: Insights from the Cancer Genome Atlas (TCGA) project. Cancers (Basel) 2019;11(8):1061. https://doi.org/10.3390/cancers11081061Bakhoum M.F., Esmaeli B. Molecular characteristics of uveal melanoma: Insights from the Cancer Genome Atlas (TCGA) project. Cancers (Basel) 2019;11(8):1061. https://doi.org/10.3390/cancers11081061Zherka I., Gulenko O., Ruksha K., et al. Influence of tumor-infiltrating T-cells’ characteristics on the survival of patients with primary choroid melanoma. ESMO Open 2024;9(1s2):P.1. https://doi.org/10.1016/j.esmoop.2024.102528Zherka I., Gulenko O., Ruksha K., et al. Influence of tumor-infiltrating T-cells’ characteristics on the survival of patients with primary choroid melanoma. ESMO Open 2024;9(1s2):P.1. https://doi.org/10.1016/j.esmoop.2024.102528Zherka I., Gulenko O., Ruksha K., et al. Influence of tumor immune infiltrate characteristics on survival rates of patients with choroid melanoma. ESMO Open 2023;8(1s3):P.1. https://doi.org/10.34883/PI.2023.11.1.015Zherka I., Gulenko O., Ruksha K., et al. Influence of tumor immune infiltrate characteristics on survival rates of patients with choroid melanoma. ESMO Open 2023;8(1s3):P.1. https://doi.org/10.34883/PI.2023.11.1.015Chauvin J.M., Zarour H.M. TIGIT in cancer immunotherapy. J Immunother Cancer 2020;8(2):e000957. https://doi.org/10.1136/jitc-2020-000957Chauvin J.M., Zarour H.M. TIGIT in cancer immunotherapy. J Immunother Cancer 2020;8(2):e000957. https://doi.org/10.1136/jitc-2020-000957Tang W., Chen J., Ji T., Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis 2023;14(7):466. https://doi.org/10.1038/s41419-023-05961-3Tang W., Chen J., Ji T., Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis 2023;14(7):466. https://doi.org/10.1038/s41419-023-05961-3Tannir N.M., Forero-Torres A., Ramchandren R., et al. Phase I dose escalation study of SGN-75 in patients with CD70-positive relapsed/ refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 2014;32(6):1246–57. https://doi.org/10.1007/s10637-014-0151-0Tannir N.M., Forero-Torres A., Ramchandren R., et al. Phase I dose escalation study of SGN-75 in patients with CD70-positive relapsed/ refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 2014;32(6):1246–57. https://doi.org/10.1007/s10637-014-0151-0Folberg R., Chen X., Boldt H.C., Pe’er J., et al. Microcirculation patterns other than loops and networks in choroidal and ciliary body melanomas. Ophthalmology 2001;108(5):996–1001. https://doi.org/10.1016/s0161-6420(01)00541-3Folberg R., Chen X., Boldt H.C., Pe’er J., et al. Microcirculation patterns other than loops and networks in choroidal and ciliary body melanomas. Ophthalmology 2001;108(5):996–1001. https://doi.org/10.1016/s0161-6420(01)00541-3Жерко И.Ю., Гуленко О.В., Рукша К.Г. и соавт. Анализ взаимосвязи характеристик опухолевого иммунного инфильтрата и показателей выживаемости пациентов с меланомой хориоидеи. Евразийский онкологический журнал 2023;11(1):47–59. https://doi.org/10.34883/Pl.2023/11/1/015.Zherka I., Gulenko O., Ruksha K., et al. Influence of Tumor Immune Infiltrate Characteristics on Survival Rates of Patients with Choroid Melanoma. Eurasian Journal of Oncology 2023;11(1):47–59 (In Russ.). https://doi.org/10.34883/Pl.2023/11/1/015Stamm H., Klingler F., Grossjohann E.M., et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene 2018;37(39):5269–80. https://doi.org/10.1038/s41388-018-0288-yStamm H., Klingler F., Grossjohann E.M., et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene 2018;37(39):5269–80. https://doi.org/10.1038/s41388-018-0288-yNishiwada S., Sho M., Yasuda S., et al. Clinical signifcance of CD155 expression in human pancreatic cancer. Anticancer Res 2015;35(4):2287–97Nishiwada S., Sho M., Yasuda S., et al. Clinical signifcance of CD155 expression in human pancreatic cancer. Anticancer Res 2015;35(4):2287–97Morimoto S., Kanno Y., Tanaka Y., et al. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol 2000;164(8):4097–104. https://doi.org/10.4049/jimmunol.164.8.4097Morimoto S., Kanno Y., Tanaka Y., et al. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol 2000;164(8):4097–104. https://doi.org/10.4049/jimmunol.164.8.4097Shang B., Liu Y., Jiang S.J., Liu Y. Prognostic value of tumor-infiltrating FoxP3 + regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015;5:15179. https://doi.org/10.1038/srep15179.Shang B., Liu Y., Jiang S.J., Liu Y. Prognostic value of tumor-infiltrating FoxP3 + regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015;5:15179. https://doi.org/10.1038/srep15179.Borst J., Hendriks J., Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005;17(3):275–81. https://doi.org/10.1016/j.coi.2005.04.004Borst J., Hendriks J., Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005;17(3):275–81. https://doi.org/10.1016/j.coi.2005.04.004Tesselaar K., Xiao Y., Arens R., et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol 2003;170(1):33–40. https://doi.org/10.4049/jimmunol.170.1.33Tesselaar K., Xiao Y., Arens R., et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol 2003;170(1):33–40. https://doi.org/10.4049/jimmunol.170.1.33Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3(8):609–20. https://doi.org/10.1038/nri1148Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3(8):609–20. https://doi.org/10.1038/nri1148Larkin J., Chiarion-Sileni V., Gonzalez R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030Larkin J., Chiarion-Sileni V., Gonzalez R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030Stanietsky N., Simic H., Arapovic J., et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci 2009;106(42):17858–17863. https://doi.org/10.1073/pnas.0903474106.Stanietsky N., Simic H., Arapovic J., et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci 2009;106(42):17858–17863. https://doi.org/10.1073/pnas.0903474106.

The authors declare that there are no conflicts of interest present.